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The incidence and prevalence of pulmonary disease caused by infections with non-tuberculous 22 
mycobacteria (NTM) is increasing worldwide. NTM-pulmonary disease requires a long-lasting therapy 23 
of up to two years which however has a success rate of less than 50% (1, 2). Mycobacterium 24 
abscessus complex (MABSC) comprised of the three subspecies Mycobacterium abscessus subsp. 25 
abscessus, Mycobacterium abscessus subsp. bolletii and Mycobacterium abscessus subsp. massiliense 26 
(3) is characterized by its extreme drug resistance to both broad-spectrum drugs and tuberculosis-27 
specific drugs (4, 5). Consequently, treatment options are limited and novel drugs are urgently 28 
needed. Unfortunately, M. abscessus drug-screens revealed a low hit rate limiting the development 29 
of drugs with a new mode of action (6, 7). However, repurposing of existing drugs might offer new 30 
treatment options (8).  31 
Rifamycins act as inhibitors of the DNA-dependent RNA polymerase (9, 10). Rifampicin (RMP), 32 
although highly active against Mycobacterium tuberculosis (critical concentration in MGIT 1.0 mg/L) 33 
(11) shows very poor growth inhibition of M. abscessus (MIC 128 mg/L) due to the drug-modifying 34 
activity of its ADP-ribosyltransferase ArrMAB (12). Arr enzymes modify the C23-hydroxyl group within 35 
the rifamycin core structure (13). Deletion of arrMab in M. abscessus has been shown not only to 36 
decrease the MIC for RMP but also for two other rifamycins, i.e. rifaximine (RFX) and rifapentine 37 
(RPT) (12).  38 
Recently, the RMP analogue rifabutin (RBT) was identified in an in vitro M. abscessus drug-screen and 39 
verified to be active against a variety of M. abscessus strains (MIC ≈ 3 mg/L) (14). Subsequently, RBT 40 
proved to be efficacious in in vitro and in vivo models of M. abscessus infection while RMP lacked 41 
activity (15, 16). The antibacterial in vitro and in vivo activity suggests that RBT unlike the other 42 
rifamycins might not be a substrate for ArrMAB although MIC of RBT for mycobacterial pathogens 43 
without arr [M. tuberculosis (critical concentrations RBT = 0.1 mg/L vs RMP 1.0 mg/) and M. avium] 44 

























































We conducted RBT susceptibility testing (Supplemental Material) of M. abscessus ATCC 19977T, its 46 
isogenic Δarr deletion mutant and the complemented mutant ΔarrMAB pMV361_arrMAB (12) to resolve 47 
this issue (Table 1; Supplemental Table S1). RFX and RMP served as a control. M. abscessus (wt) 48 
showed a RBT MIC of 4 mg/L, while MICs for rifaximine (RFX; 32 mg/L) and particularly for RMP (128 49 
mg/L) were considerably higher. The M. abscessus ΔarrMAB mutant exhibited increased susceptibility 50 
to RMP, RFX and particularly towards RBT (Table 1). The log2-transformed relative resistance ratios 51 
(RRR) MICwt/MICΔarr for RBT, RFX and RMP were 18, 4 and 8, respectively. The MICs of other drug 52 
classes [amikacin (AMK), tetracycline (TET)] were not affected by the arr genotype (RRR = 0 – 1). The 53 
wild-type MICs towards the rifamycins were restored in the complemented deletion mutant. The low 54 
RBT MIC of the M. abscessus Δarr deletion mutant indicates that RBT is a substrate for Arr. 55 
Furthermore, the lower RRR for RMP as compared to the RRR for RBT (8 vs. 18) suggests that 56 
resistance determinants other than Arr might selectively inactivate RMP but not RBT.  57 
RMP monooxygenases (Rox) are present in a wide variety of environmental bacteria and are 58 
associated with decomposition of RMP (17). A corresponding rifamycin resistance mechanism has 59 
also been proposed for M. abscessus (18). Using Rox genes of Streptomyces venezuelae (Sven_0481) 60 
and Nocardia farcinica (Nfa_35080) as a query in a BlastP search putative M. abscessus orthologues 61 
MAB_0857, MAB_3484 and MAB_1496c were identified (Supplemental Table S2). Of these, 62 
MAB_1496c has recently been demonstrated to be a member of the M. abscessus resistome due to 63 
its involvement in tetracycline oxygenation (19). Single and multiple unmarked deletion mutants 64 
(Figure 1; Supplemental Figure S1) in M. abscessus ATCC 19977T and M. abscessus Δarr were 65 
constructed by allelic replacement with suicide vectors containing PCR-amplified flanking regions of 66 
the target genes (Supplemental Table S3) and apramycin-positive and katG (INH
S
)-negative selection 67 
markers (20, 21) (Fig. 1). Mutants were confirmed by PCR and Southern blot analysis (Supplemental 68 
Figure S1) and tested for rifamycin, tetracycline and amikacin susceptibility (Table 1). Exploratory 69 
investigations indicated that neither individual deletion of MAB_0857, MAB_3483 and MAB_1496c 70 

























































RFX, RMP and AMK MIC, respectively. Likewise, deletion of these genes in M. abscessus ΔarrMAB did 72 
not alter susceptibility towards these antibiotics as compared to M. abscessus ΔarrMAB indicating that 73 
these genes do not affect rifamycins. Deletion of MAB_1496c, encoding monooxygenase TetX 74 
decreased the tetracycline MIC 16 -32-fold, while rifamycin MICs were not affected (for the MIC of 75 
the most advanced strains see Table 1).  76 
So far, our investigations have not identified genetic determinants responsible for selective RMP 77 
modification. A phenotypic screen of a genome wide transposon mutant library might be the most 78 
efficient way to identify those resistance determinants (22, 23). However, our findings on RBT 79 
susceptibility of the Δarr mutant are of major importance for future drug development. The RRR of 80 
about 250.000 (log2=18) clearly shows that RBT is a substrate of Arr which in turn suggests that the 81 
potency of RBT against M. abscessus might be improved by either Arr-inhibitors or by RBT 82 
modification. Regimens co-applying drugs in conjunction with inhibitors of drug-modifying enzymes 83 
have been developed to restore antibiotic activity and are widely used in clinics (24-26). Similarly, 84 
Arr-inhibitors might be beneficial to establish a rifamycin-based treatment for M. abscessus 85 
infections. Alternatively modifications of the drug itself might render RBT resilient towards Arr. E.g. 86 
substitution of the acetyl moiety by a bulky residue at position C25 rendered RMP partially resistant 87 
towards Arr-modification (12, 27, 28). We envision that these approaches may improve treatment 88 
options and outcomes of pulmonary disease caused by the opportunistic pathogen feared for its 89 
high-level drug resistance, M. abscessus. 90 
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Table 1: Minimal Inhibitory Concentration (MIC)* and Relative Resistance Ratios (RRR)** of strains 200 
Strain RBT RFX RMP TET AMK 
 MIC RRR MIC RRR MIC RRR MIC RRR MIC RRR 
M. abscessus 4 / 32 / 128 / 32 / 1 / 
ΔarrMAB 1.1x10-5 18 1.5 4 0.38 8 24 0 1 0 
ΔarrMAB  
pMV361-arrMab 











 16 1.5 4 0.19 9 1 5 1 0 
*MIC (median of 6 replicates) in mg/L; **Relative Resistance Ratio (RRR) log2 MICwt/MICcomparator 201 
 202 
 203 


























































Figure 1 206 
Genealogy of strains 207 
 208 
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